VERTEX PHARMACEUTICALS INC / MA
VRTX · XNASCIK 875320fmd_17RDSX9EHS4JAPTCN1CCDNFDKHManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2008 to Sep 30, 2026, 72 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 1,702 | 2,489 | 3,048 | 4,163 | 6,206 | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 |
| Cost of revenue | 210 | 275 | 410 | 548 | 736 | 904 | 1,080 | 1,262 | 1,531 | 1,651 |
| Net interest income | – | – | – | (59) | (58) | (62) | (55) | (44) | – | – |
| Gross profit | 1,492 | 2,214 | 2,638 | 3,615 | 5,469 | 6,670 | 7,850 | 8,607 | 9,490 | 10,350 |
| Research and development | 1,048 | 1,325 | 1,416 | 1,755 | 1,645 | 1,938 | 2,540 | 3,163 | 3,630 | 3,910 |
| Selling, general and administrative | 433 | 496 | 558 | 658 | 770 | 840 | 945 | 1,137 | 1,464 | 1,753 |
| Operating income | 10 | 123 | 635 | 1,198 | 2,856 | 2,782 | 4,307 | 3,832 | (233) | 4,173 |
| Interest expense | – | 69 | 72 | 59 | 58 | – | 55 | 44 | 31 | 13 |
| Interest and investment income | – | 12 | 38 | 64 | 22 | 5 | 145 | 615 | 598 | 491 |
| Other non-operating income (expense) | 4 | (81) | (1) | 192 | 297 | 5 | (165) | (23) | (86) | (8) |
| Income before taxes | (67) | (16) | 600 | 1,395 | 3,117 | 2,730 | 4,232 | 4,380 | 249 | 4,643 |
| Income tax expense | 17 | (107) | (1,487) | 218 | 405 | 388 | 910 | 760 | 784 | 690 |
| Net income from continuing operations | (84) | 92 | 2,087 | 1,177 | 2,712 | 2,342 | 3,322 | 3,620 | (536) | 3,953 |
| Net income | (112) | 263 | 2,097 | 1,177 | 2,712 | 2,342 | 3,322 | 3,620 | (536) | 3,953 |
| Net income to common shareholders | (112) | 263 | 2,096 | 1,177 | 2,712 | – | – | – | – | – |